Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. --(BUSINESS WIRE)--Dec. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive

BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 22, 2024-- Quanterix Corporation   (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q

Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 12, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial

BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 5, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024 , at 4:30 p.m. E.T.

LucentAD TM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients BILLERICA, Mass. --(BUSINESS WIRE)--Oct. 28, 2024-- Lucent Diagnostics , a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a

BILLERICA, Mass. --(BUSINESS WIRE)--Oct. 2, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D.

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 30, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 19, 2024-- Quanterix Corporation   (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr.

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 8, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024 . “Our research business once again delivered